These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28220465)

  • 1. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes.
    Saeed A; Ballantyne CM
    Curr Cardiol Rep; 2017 Mar; 19(3):19. PubMed ID: 28220465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk.
    Billups KL; Miner MM; Wierzbicki AS; Jackson G
    Int J Clin Pract; 2011 Feb; 65(2):134-47. PubMed ID: 21199197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: A retrospective study.
    Chung YK; Lee YJ; Kim KW; Cho RK; Chung SM; Moon JS; Yoon JS; Won KC; Lee HW
    Diab Vasc Dis Res; 2018 Jan; 15(1):24-30. PubMed ID: 29090609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk in youth with diabetes mellitus.
    Wadwa RP
    Rev Endocr Metab Disord; 2006 Sep; 7(3):197-204. PubMed ID: 17160723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial dysfunction and cardiovascular disease in type 2 diabetes.
    Ofstad AP
    Scand J Clin Lab Invest; 2016 Jul; 76(4):271-81. PubMed ID: 27071642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of cardiovascular disease in type 2 diabetes].
    Paquot N; Scheen AJ
    Rev Med Liege; 2003 May; 58(5):271-4. PubMed ID: 12940113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus.
    Soma P; Pretorius E
    Cardiovasc Diabetol; 2015 Jul; 14():96. PubMed ID: 26228646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.
    Tushuizen ME; Diamant M; Heine RJ
    Postgrad Med J; 2005 Jan; 81(951):1-6. PubMed ID: 15640422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual renal and cardiovascular disease risk in conventionally-treated patients with type 2 diabetes: the potential of non-traditional biomarkers.
    Zitouni K; Steyn M; Earle KA
    Minerva Med; 2018 Apr; 109(2):103-115. PubMed ID: 29164839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative imaging biomarkers for the evaluation of cardiovascular complications in type 2 diabetes mellitus.
    Lin K; Lloyd-Jones DM; Li D; Carr JC
    J Diabetes Complications; 2014; 28(2):234-42. PubMed ID: 24309215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.
    Manson JE; Colditz GA; Stampfer MJ; Willett WC; Krolewski AS; Rosner B; Arky RA; Speizer FE; Hennekens CH
    Arch Intern Med; 1991 Jun; 151(6):1141-7. PubMed ID: 2043016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherosclerosis associated with dynamic inflammation changes after multifactorial intervention in short-duration type 2 diabetes: A randomized, controlled, 10-year follow-up trial.
    Shi C; Men L; Yu C; Yao J; Bai R; Yang Y; Sun L; Sun G; Song G; Zhang Y; Xing Q; Du J
    J Diabetes Complications; 2017 Aug; 31(8):1286-1292. PubMed ID: 28610945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Framingham risk equations underestimate coronary heart disease risk in diabetes.
    Stevens RJ; Coleman RL; Holman RR
    Diabet Med; 2005 Feb; 22(2):228. PubMed ID: 15660747
    [No Abstract]   [Full Text] [Related]  

  • 16. Lens changes and the incidence of cardiovascular events among persons with diabetes.
    Podgor MJ; Kannel WB; Cassel GH; Sperduto RD
    Am Heart J; 1989 Mar; 117(3):642-8. PubMed ID: 2919539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.
    Jung CH; Mok JO
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):260-271. PubMed ID: 32615710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities.
    Steiner G
    Diabetes Care; 1999 Apr; 22 Suppl 3():C6-9. PubMed ID: 10189556
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular complications of diabetes.
    Lau DC; Shen GX
    Can J Diabetes; 2013 Oct; 37(5):279-81. PubMed ID: 24500552
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of handgrip strength with B-type natriuretic peptide levels and cardiovascular events in patients with type 2 diabetes.
    Hamasaki H
    Diabetes Metab; 2019 Apr; 45(2):209-211. PubMed ID: 28751101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.